Tezosentan
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H27N9O6S |
Molar mass | 605.63 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]
References
- ^ Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, et al. (December 2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut. 53 (12). BMJ Publishing Group Ltd & British Society of Gastroenterology: 1844–9. doi:10.1136/gut.2003.036517. PMC 1774327. PMID 15542526.
- ^ "Tezosentan does not appear to improve symptoms for patients with acute heart failure". Medical Studies/Trials. news-medical.net. 7 Nov 2007. Retrieved 2007-11-24.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Vasodilators
- Tetrazoles
- Pyridines
- Pyrimidines
- Phenol ethers
- Sulfonamides
- Alcohols
- Endothelin receptor antagonists
- Isopropyl compounds
- Diaryl ethers
- All stub articles
- Cardiovascular system drug stubs